Andre J Scheen
Overview
Explore the profile of Andre J Scheen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
231
Citations
4019
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scheen A
Diabetes Metab
. 2025 Jan;
51(2):101612.
PMID: 39818408
Background: Obesity is an increasing public health problem because of its high prevalence and associated morbidity and mortality. Two weight-loss strategies are currently used, either bariatric surgery or pharmacological therapy...
2.
Scheen A
Diabetes Metab
. 2024 Nov;
51(1):101594.
PMID: 39608670
Background: Combining a glucagon-like peptide-1 receptor agonist (GLP-1RA) and an sodium-glucose cotransporter 2 inhibitor (SGLT2i) improved cardiovascular (and renal) prognosis compared to either monotherapy in several post-hoc exploratory analyses of...
3.
Scheen A
Drugs
. 2024 Sep;
84(11):1347-1364.
PMID: 39342059
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) have proven efficacy and safety in randomized clinical trials and observational real-life studies. Besides improving glucose control, reducing body...
4.
Scheen A
Lancet Diabetes Endocrinol
. 2024 Sep;
12(10):685-687.
PMID: 39250920
No abstract available.
5.
Scheen A
Rev Med Suisse
. 2024 Sep;
20(884):1498-1502.
PMID: 39219393
SGLT2 inhibitors (gliflozins) have proven their efficacy in reducing complications due to atherosclerotic cardiovascular disease, heart failure and chronic kidney disease both in placebo-controlled clinical trials and in real-life studies...
6.
Scheen A, Paquot N
Rev Med Suisse
. 2024 Sep;
20(884):1492-1497.
PMID: 39219392
Both glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiorenal -prognosis of at-risk patients with type 2 diabetes thanks to pleiotropic effects that are either common...
7.
8.
Scheen A
Expert Opin Drug Saf
. 2024 May;
23(7):797-810.
PMID: 38738549
Introduction: Patients with type 2 diabetes (T2DM) are at high risk of atherosclerotic cardiovascular disease (ASCVD) and cardiovascular death. Cardiovascular protection is a key objective in T2DM. Areas Covered: Glucagon-like...
9.
Scheen A
Diabetes Metab
. 2023 Dec;
50(2):101508.
PMID: 38158077
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is), while developed as antihyperglycaemic medications for the treatment of type 2 diabetes, have proven to reduce major cardiovascular...
10.
Scheen A
Expert Rev Clin Pharmacol
. 2023 Nov;
16(11):1053-1062.
PMID: 37919944
Introduction: Atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF) are two major complications of type 2 diabetes (T2DM). Cardiovascular protection is a key objective, yet not fully reached in clinical...